-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QaBub4a8Vk2Je1Zqlr3wzVcv0I3wJ7WXgvPHiCfIQS377Aq5Vd4LtEi8jB9+VcXJ mPPhqYPbIgkY1fsf2bzTyQ== 0000950142-00-000237.txt : 20000317 0000950142-00-000237.hdr.sgml : 20000317 ACCESSION NUMBER: 0000950142-00-000237 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20000316 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20000316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EMISPHERE TECHNOLOGIES INC CENTRAL INDEX KEY: 0000805326 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133306985 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-10615 FILM NUMBER: 571669 BUSINESS ADDRESS: STREET 1: 765 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143472220 MAIL ADDRESS: STREET 1: 765 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: CLINICAL TECHNOLOGIES ASSOCIATES INC DATE OF NAME CHANGE: 19920128 8-K 1 CURRENT REPORT ON FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2000 EMISPHERE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 1-10615 13-3306985 -------- ------- ---------- (State or other (Commission (IRS Employer jurisdiction of File No.) Identification No.) incorporation) 765 Old Saw Mill River Road, Tarrytown, New York 10591 ------------------------------------------------ ----- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (914) 347-2220 Item 5. Other Events. ------------- Emisphere Technologies, Inc. ("Emisphere" or the "Company") announced today that it is initiating clinical testing of a solid oral dosage form of heparin. The study is a Phase I safety and tolerability study in healthy subjects and is being conducted in the United Kingdom. In animal models leading to the commencement of this study, Emisphere has demonstrated that its solid dosage form of heparin does not require heparin amounts greater than what is contained in the Company's liquid dosage form, currently in Phase III development, to achieve a comparable therapeutic response and bioavailability to the liquid dosage form. Signatures ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: March 16, 2000 EMISPHERE TECHNOLOGIES, INC. /s/ Charles H. Abdalian ----------------------- Name: Chalres H. Abdalian, Jr. Title: Vice President, Chief Finaicial Officer and Secretary -----END PRIVACY-ENHANCED MESSAGE-----